{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T21:44:10Z","timestamp":1792619050723,"version":"4.5.0"},"reference-count":57,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","clinical-genitourinary-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.clgc.2024.102066","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T16:42:05Z","timestamp":1709916125000},"page":"102066","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Cardiovascular Toxicity Associated With Androgen Receptor Axis-Targeted Agents in Patients With Prostate Cancer: A Meta-analysis of Randomized Controlled Trials"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5653-999X","authenticated-orcid":false,"given":"Susu","family":"Zhou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Parissa","family":"Alerasool","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5007-8808","authenticated-orcid":false,"given":"Noriko","family":"Kishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0272-0733","authenticated-orcid":false,"given":"Himanshu","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3503-6041","authenticated-orcid":false,"given":"Gagan","family":"Sahni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Che-Kai","family":"Tsao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2024.102066_bib0001","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"issue":"9","key":"10.1016\/j.clgc.2024.102066_bib0002","article-title":"Prostate cancer","volume":"7","author":"Rebello","year":"2021","journal-title":"Nat Rev Dis Primers."},{"key":"10.1016\/j.clgc.2024.102066_bib0003","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3322\/canjclin.22.4.232","article-title":"Studies on prostatic cancer. I. The effect of castration, of estrogen and androgen injection on serum phosphatases in metastatic carcinoma of the prostate","volume":"22","author":"Huggins","year":"1972","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clgc.2024.102066_bib0004","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/bjc.2012.523","article-title":"Endocrine therapy in prostate cancer: time for reappraisal of risks, benefits and cost-effectiveness?","volume":"108","author":"Bourke","year":"2013","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clgc.2024.102066_bib0005","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1038\/s41585-019-0237-8","article-title":"Towards precision oncology in advanced prostate cancer","volume":"16","author":"Ku","year":"2019","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2024.102066_bib0006","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pharmthera.2013.07.003","article-title":"Androgen receptors in hormone-dependent and castration-resistant prostate cancer","volume":"140","author":"Shafi","year":"2013","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clgc.2024.102066_bib0007","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1038\/onc.2013.206","article-title":"Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches","volume":"32","author":"Karantanos","year":"2013","journal-title":"Oncogene"},{"key":"10.1016\/j.clgc.2024.102066_bib0008","doi-asserted-by":"crossref","first-page":"20","DOI":"10.4103\/1477-3163.83937","article-title":"Androgen receptor signaling in prostate cancer development and progression","volume":"10","author":"Lonergan","year":"2011","journal-title":"J Carcinog"},{"key":"10.1016\/j.clgc.2024.102066_bib0009","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMc1803343","article-title":"Metastatic prostate cancer","volume":"378","author":"Rodriguez\u2011Moreno","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102066_bib0010","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1146\/annurev-pharmtox-052220-015912","article-title":"A new old target: androgen receptor signaling and advanced prostate cancer","volume":"62","author":"Westaby","year":"2022","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.clgc.2024.102066_bib0011","article-title":"Recent trends in the management of advanced prostate cancer","volume":"7","author":"Ritch","year":"2018"},{"key":"10.1016\/j.clgc.2024.102066_bib0012","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1146\/annurev-med-051517-011947","article-title":"Treatment of advanced prostate cancer","volume":"70","author":"Teo","year":"2019","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.clgc.2024.102066_bib0013","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","article-title":"Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer","volume":"133","author":"Bhatia","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.clgc.2024.102066_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188383","article-title":"Cardiovascular risks and toxicity: the Achilles heel of androgen deprivation therapy in prostate cancer patients","volume":"1874","author":"Muniyan","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.clgc.2024.102066_bib0015","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s11864-021-00846-z","article-title":"Cardiovascular toxicities of androgen deprivation therapy","volume":"22","author":"Challa","year":"2021","journal-title":"Curr Treat Options Oncol"},{"key":"10.1016\/j.clgc.2024.102066_bib0016","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.3390\/curroncol28050289","article-title":"Androgen deprivation therapy, hypogonadism and cardiovascular toxicity in men with advanced prostate cancer","volume":"28","author":"Gheorghe","year":"2021","journal-title":"Curr Oncol"},{"key":"10.1016\/j.clgc.2024.102066_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.695170","article-title":"Does exist a differential impact of degarelix versus LHRH agonists on cardiovascular safety? Evidences from randomized and real-world studies","volume":"12","author":"Sciarra","year":"2021","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.clgc.2024.102066_bib0018","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.31429","article-title":"Comparing cardiovascular outcomes with degarelix or leuprolide as prostate cancer therapy-applying real-world data to clinical trial emulation","volume":"4","author":"Narayan","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2024.102066_bib0019","doi-asserted-by":"crossref","first-page":"68","DOI":"10.14797\/mdcj-13-2-68","article-title":"Testosterone and the Heart","volume":"13","author":"Goodale","year":"2017","journal-title":"Methodist Debakey Cardiovasc J"},{"key":"10.1016\/j.clgc.2024.102066_bib0020","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1210\/jcem.86.9.7851","article-title":"The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer","volume":"86","author":"Smith","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clgc.2024.102066_bib0021","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.19568","article-title":"Causes of death among patients with metastatic prostate cancer in the US from 2000 to 2016","volume":"4","author":"Elmehrath","year":"2021","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.clgc.2024.102066_bib0022","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.clgc.2024.102066_bib0023","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.clgc.2024.102066_bib0024","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.cegh.2018.05.005","article-title":"Interpretation of subgroup analyses in systematic reviews: a tutorial","volume":"7","author":"Richardson","year":"2019","journal-title":"Clin Epidemiol Glob Health"},{"key":"10.1016\/j.clgc.2024.102066_bib0025","unstructured":"Review Manager (RevMan) [Computer program] Version 5.4 TCC, 2020."},{"key":"10.1016\/j.clgc.2024.102066_bib0026","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase iii study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102066_bib0027","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.eururo.2016.07.032","article-title":"Enzalutamide in men with chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study","volume":"71","author":"Beer","year":"2017","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102066_bib0028","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102066_bib0029","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.102066_bib0030","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.102066_bib0031","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","article-title":"Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide","volume":"383","author":"Fizazi","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102066_bib0032","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/S1470-2045(22)00560-5","article-title":"Continuous enzalutamide after progression of metastatic castration-resistant prostate cancer treated with docetaxel (PRESIDE): an international, randomised, phase 3b study","volume":"23","author":"Merseburger","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.102066_bib0033","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1007\/s12325-022-02140-2","article-title":"Enzalutamide in chemotherapy-na\u00efve metastatic castration-resistant prostate cancer: an Asian multiregional, randomized study","volume":"39","author":"Pu","year":"2022","journal-title":"Adv Ther"},{"key":"10.1016\/j.clgc.2024.102066_bib0034","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.102066_bib0035","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S1470-2045(21)00402-2","article-title":"Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study","volume":"22","author":"Saad","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2024.102066_bib0036","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102066_bib0037","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.eururo.2020.08.011","article-title":"Apalutamide and overall survival in prostate cancer","volume":"79","author":"Smith","year":"2021","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102066_bib0038","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102066_bib0039","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","article-title":"Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer","volume":"382","author":"Sternberg","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102066_bib0040","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1111\/iju.13051","article-title":"Abiraterone acetate for metastatic castration-resistant prostate cancer after docetaxel failure: a randomized, double-blind, placebo-controlled phase 3 bridging study","volume":"23","author":"Sun","year":"2016","journal-title":"Int J Urol"},{"key":"10.1016\/j.clgc.2024.102066_bib0041","doi-asserted-by":"crossref","first-page":"29661","DOI":"10.1074\/jbc.M411694200","article-title":"Androgen receptor gene knockout male mice exhibit impaired cardiac growth and exacerbation of angiotensin II-induced cardiac fibrosis","volume":"280","author":"Ikeda","year":"2005","journal-title":"J Biol Chem"},{"key":"10.1016\/j.clgc.2024.102066_bib0042","doi-asserted-by":"crossref","first-page":"R131","DOI":"10.1530\/JOE-14-0611","article-title":"Androgen receptor in human endothelial cells","volume":"224","author":"Torres-Estay","year":"2015","journal-title":"J Endocrinol"},{"key":"10.1016\/j.clgc.2024.102066_bib0043","first-page":"183","article-title":"Androgen actions on endothelium functions and cardiovascular diseases","volume":"13","author":"Cai","year":"2016","journal-title":"J Geriatr Cardiol"},{"key":"10.1016\/j.clgc.2024.102066_bib0044","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/aja.2012.21","article-title":"Testosterone and cardiovascular disease in men","volume":"14","author":"Morris","year":"2012","journal-title":"Asian J Androl"},{"key":"10.1016\/j.clgc.2024.102066_bib0046","doi-asserted-by":"crossref","first-page":"e645","DOI":"10.1016\/j.clgc.2017.12.007","article-title":"The cardiovascular toxicity of abiraterone and enzalutamide in prostate cancer","volume":"16","author":"Iacovelli","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2024.102066_bib0047","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/s41391-020-00275-3","article-title":"Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses","volume":"24","author":"Lee","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.clgc.2024.102066_bib0048","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1080\/17425255.2021.1970745","article-title":"Risk of cardiovascular toxicities and hypertension in nonmetastatic castration-resistant prostate cancer patients treated with novel hormonal agents: a systematic review and meta-analysis","volume":"17","author":"Rizzo","year":"2021","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.clgc.2024.102066_bib0049","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1093\/jnci\/djac081","article-title":"Risk of metabolic and cardiovascular adverse events with abiraterone or enzalutamide among men with advanced prostate cancer","volume":"114","author":"Lai","year":"2022","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.clgc.2024.102066_bib0050","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1056\/NEJMe2016433","article-title":"Cardiovascular disease and androgen axis-targeted drugs for prostate cancer","volume":"382","author":"Higano","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2024.102066_bib0051","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.eururo.2016.06.041","article-title":"Docetaxel for metastatic hormone-sensitive prostate cancer: urgent need to minimize the risk of neutropenic fever","volume":"70","author":"Tsao","year":"2016","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2024.102066_bib0052","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1200\/JCO.2010.30.7025","article-title":"Castration-dependent pharmacokinetics of docetaxel in patients with prostate cancer","volume":"28","author":"Franke","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2024.102066_bib0053","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","article-title":"Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial","volume":"28","author":"Powles","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.clgc.2024.102066_bib0054","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2023.104059","article-title":"Comparing cardiovascular adverse events in cancer patients: a meta-analysis of combination therapy with angiogenesis inhibitors and immune checkpoint inhibitors versus angiogenesis inhibitors alone","volume":"188","author":"Crocetto","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clgc.2024.102066_bib0055","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41371-020-00400-8","article-title":"Hypertension and cardiovascular risk factors when treating cancer patients: underrecognised and undertreated","volume":"35","author":"Essa","year":"2021","journal-title":"J Hum Hypertens"},{"key":"10.1016\/j.clgc.2024.102066_bib0056","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jaccao.2023.01.010","article-title":"Risk of cancer after diagnosis of cardiovascular disease","volume":"5","author":"Bell","year":"2023","journal-title":"JACC CardioOncol"},{"key":"10.1016\/j.clgc.2024.102066_bib0057","doi-asserted-by":"crossref","first-page":"512","DOI":"10.3390\/jpm13030512","article-title":"Bladder cancer and risk factors: data from a multi-institutional long-term analysis on cardiovascular disease and cancer incidence","volume":"13","author":"Barone","year":"2023","journal-title":"J Pers Med"},{"key":"10.1016\/j.clgc.2024.102066_bib0058","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","article-title":"Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer","volume":"133","author":"Bhatia","year":"2016","journal-title":"Circulation."}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000399?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767324000399?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T04:00:35Z","timestamp":1717646435000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767324000399"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":57,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1558767324000399"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102066","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Toxicity Associated With Androgen Receptor Axis-Targeted Agents in Patients With Prostate Cancer: A Meta-analysis of Randomized Controlled Trials","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2024.102066","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102066"}}